Compare HOVR & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | ALGS |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.5M | 43.0M |
| IPO Year | N/A | 2020 |
| Metric | HOVR | ALGS |
|---|---|---|
| Price | $1.86 | $7.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $10.33 | ★ $46.67 |
| AVG Volume (30 Days) | ★ 500.2K | 33.8K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.35 | $3.76 |
| 52 Week High | $4.18 | $13.69 |
| Indicator | HOVR | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 48.76 |
| Support Level | $1.69 | $6.92 |
| Resistance Level | $1.90 | $7.50 |
| Average True Range (ATR) | 0.15 | 0.54 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 45.71 | 73.11 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.